ArticlePloS one2011
Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence.Human vaccines & immunotherapeutics · 2019Pooled it
- Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer.PharmacoEconomics · 2016Pooled it
- Economic evaluation of vaccines in Canada: A systematic review.Human vaccines & immunotherapeutics · 2016Pooled it
- Natural attack rate of influenza in unvaccinated children and adults: a meta-regression analysis.BMC infectious diseases · 2014Pooled it
- Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison.Human vaccines & immunotherapeutics · 2013Trial
- Article
- Improving policy design and epidemic response using integrated models of economic choice and disease dynamics with behavioral feedback.PLoS computational biology · 2025Article
- Review
- Article
- Reducing dengue fever cases at the lowest budget: a constrained optimization approach applied to Thailand.BMC public health · 2021Article
- Review
- The economic impact and cost-effectiveness of combined vector-control and dengue vaccination strategies in Thailand: results from a dynamic transmission model.PLoS neglected tropical diseases · 2020Article
- Article
- Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population.Human vaccines & immunotherapeutics · 2018Article
- Variation in loss of immunity shapes influenza epidemics and the impact of vaccination.BMC infectious diseases · 2017Article
- Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.Human vaccines & immunotherapeutics · 2017Review
- Economic evaluations of vaccines in Canada: a scoping review.Cost effectiveness and resource allocation : C/E · 2017Article
- Integrating Transgenic Vector Manipulation with Clinical Interventions to Manage Vector-Borne Diseases.PLoS computational biology · 2016Article
- A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.Infectious diseases and therapy · 2015Article
- Estimated impact of aggressive empirical antiviral treatment in containing an outbreak of pandemic influenza H1N1 in an isolated First Nations community.Influenza and other respiratory viruses · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe propensity for influenza viruses to mutate and recombine makes them both a familiar threat and a prototype emerging infectious disease. Emerging evidence suggests that the use of MF59-adjuvanted vaccines in older adults and young children enhances protection against influenza infection and reduces adverse influenza-attributable outcomes compared to unadjuvanted vaccines. The health and economic impact of such vaccines in the Canadian population are uncertain.
methodsWe constructed an age-structured compartmental model simulating the transmission of influenza in the Canadian population over a ten-year period. We compared projected health outcomes (quality-adjusted life years (QALY) lost), costs, and incremental cost-effectiveness ratios (ICERs) for three strategies: (i) current use of unadjuvanted trivalent influenza vaccine; (ii) use of MF59-adjuvanted influenza vaccine adults ≥65 in the Canadian population, and (iii) adjuvanted vaccine used in both older adults and children aged < 6.
resultsIn the base case analysis, use of adjuvanted vaccine in older adults was highly cost-effective (ICER = $2111/QALY gained), but such a program was "dominated" by a program that extended the use of adjuvanted vaccine to include young children (ICER = $1612/QALY). Results were similar whether or not a universal influenza immunization program was used in other age groups; projections were robust in the face of wide-ranging sensitivity analyses.
interpretationBased on the best available data, it is projected that replacement of traditional trivalent influenza vaccines with MF59-adjuvanted vaccines would confer substantial benefits to vaccinated and unvaccinated individuals, and would be economically attractive relative to other widely-used preventive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.